about
The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after firOfatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSKA systematic review and economic evaluation of diagnostic strategies for Lynch syndromeThe effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic modelThe effectiveness and cost-effectiveness of methods of storing donated kidneys from deceased donors: a systematic review and economic model.Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.Improved curve fits to summary survival data: application to economic evaluation of health technologies.Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients.Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer.The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model.Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer.Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and eAzacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.Whose costs and benefits? Why economic evaluations should simulate both prevalent and all future incident patient cohorts.Future drug prices and cost-effectiveness analyses.T helper cell type 2 responsiveness predicts future susceptibility to gastrointestinal nematodes in humans.Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma.Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma.Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.Evolution of a cost-utility model of donepezil for Alzheimer's disease.Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.A search theory model of patch-to-patch forager movement with application to pollinator-mediated gene flow.The effect of wind direction on cross-pollination in wind-pollinated GM cropsEverolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysisCorrection to: Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Clinical Excellence Single Technology AppraisalCost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid LeukemiaCytokine response profiles predict species-specific infection patterns in human GI nematodesEMA and NICE Appraisal Processes for Cancer Drugs: Current Status and UncertaintiesThree biomarker tests to help diagnose preterm labour: a systematic review and economic evaluationCauses of the species-area relationship by trophic level in a field-based microecosystemReply: SUN BEVIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
P50
Q26851531-B54FB05D-221E-474F-9175-FF3573C58849Q26996599-A67A12E0-27AB-4AD8-8E84-71FC4FA96066Q27002349-2B5BCDDB-E1F8-4400-93F0-F7BD6C1068E8Q28079351-09A5E617-2A7D-4EA3-80FE-02ED1F6CBF1CQ33492999-326B8FAB-A948-449A-AA87-05B3CA07D28BQ33520386-D8A12E8B-8FF8-4981-AE47-E29702C882F1Q34045267-352AA488-E381-47B0-A8B3-EF8716AC9159Q34487826-F83DF3C8-1137-4D1B-B570-66E0EADBBD71Q35596050-D46D1865-0B22-481C-B84A-46AD3E15A474Q37214304-3C88AC9C-A7BB-460E-86FD-A0314F73F1CEQ37607408-CBB20031-678A-4AA2-9288-6F4065D5261FQ37608699-2CE93998-4399-4646-A242-CAF0EFBAAB48Q38058383-29864B13-5932-4796-8B83-38A377D10CB5Q38691353-4D74A7AF-251A-40B2-8118-17A184FF100DQ38983626-1389E49C-FA48-4D2A-8CA7-DB0BDA39EA43Q39891975-17827F65-AF74-459D-9CBB-FE6ADD465FACQ40079789-AB5A69B1-1C3E-48D6-8A83-5807E6F0F1FDQ40473905-88417340-B4AE-4727-B6B5-1E3DC695DB62Q43267004-F7538F4B-CE58-4D49-BF58-2C8BCC430867Q43267005-ECF36D8F-EE60-407A-BDD5-19AD56059135Q44029131-801C14EC-5993-4D9D-B8DB-EBE9C66098B7Q44984259-04856718-A0EA-4645-A27B-A5F744992CD6Q45959235-62D3180C-A620-4ACA-9EC7-E63A5DD2BE82Q47269302-0D5F79B8-33DC-40E7-A3FE-FE1D70F4762AQ52677759-3D9DFE63-C2FC-40D2-9F7C-1497D0F93FBDQ52680351-F02D16F4-BC77-4C8D-9377-2B85DDA6D2F2Q57123610-F0C7A0B2-A882-4724-A254-E68EB87A8ECDQ57164029-B14BBC33-1F1C-4524-89D5-01F92852F89FQ57925205-AFE97B1F-8DC1-4FD4-B9BC-97C788E9B0ADQ57938017-B8C7AA39-E3F8-4ABD-B424-8C39A7AA972EQ58227438-886F381D-E5E3-4B71-8E48-975D2EBF27A0Q58765288-08F91064-2F99-4FDB-8C79-564DE087925EQ64077532-593C24E7-3A3E-42E3-BE40-5B279941C05DQ80441266-A2E21AB5-B18B-4B75-9A8A-6E50B5AA1C6AQ93489203-90A23F1E-4134-4E04-A22B-987E6676779C
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Martin Hoyle
@en
Martin Hoyle
@nl
type
label
Martin Hoyle
@en
Martin Hoyle
@nl
prefLabel
Martin Hoyle
@en
Martin Hoyle
@nl
P31
P496
0000-0001-5593-9777